Episode 101. FDA’s prescription for corruption w/ Kim Witczak

In this clip, Kim Witczak, a consumer representative on the FDA's Psychopharmacologic Drugs Advisory Committee, discusses the approval of Lexapro for children as young as 7 years old. Dr. Roger McFillin points out that the drug was associated with a six-fold increase in suicidality in the clinical trials, and that it did not outperform placebo on three of the four outcome measures. Kim provides an overview of roles within the FDA advisory committee, revealing bias in favor of the pharmaceutical industry. Witczak calls for a more independent and transparent drug approval process.